Clinical Trials Update: April 12, 2006

Breast Cancer Peripheral Arterial Occlusive Disease Ovarian Cancer or Peritoneal Cancer

(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:

Breast Cancer

This is a multi-center, randomized, open-label study evaluating the safety and efficacy of SU011248 versus standard care. Patients who have recurrent or metastatic breast cancer, prior treatment with an anthracycline and a taxane in the adjuvant or advanced disease setting, and do not have history of inflammatory breast cancer may be eligible. The research sites are located across the United States.

More information

Please see http://www.centerwatch.com/patient/studies/cat29.html.

-----

Peripheral Arterial Occlusive Disease

This research study will evaluate the safety and effectiveness of study drug intra-thrombus alfimeprase 0.3mg/kg in people with acute peripheral arterial occlusion (PAO). Volunteers at least 18 with arteriographically confirmed acute PAO of the lower extremity with onset of symptoms within 14 days prior to study may qualify. Other conditions apply. The research sites are in Harrisburg, Penn., and Oklahoma City, Okla.

More information

Please see http://www.centerwatch.com/patient/studies/cat204.html.

-----

Ovarian Cancer or Peritoneal Cancer

This study will evaluate whether the study drug patupilone is effective in shrinking tumors and preventing the growth of cells that cause ovarian, fallopian or peritoneal cancer. Women at least 18 diagnosed with ovarian, primary fallopian, or primary peritoneal cancer who do not have gastrointestinal problems, unresolved diarrhea, heart problems, or received radiation or chemotherapy within the last four weeks may be eligible. The research sites are throughout the United States.

More information

Please see http://www.centerwatch.com/patient/studies/cat186.html or http://www.centerwatch.com/patient/studies/cat553.html.

-----

Copyright 2006 CenterWatch. All rights reserved.

http://www.centerwatch.com/patient/studies/cat553.html
Consumer News